KOL Perspectives: Adaptive Trial Designs in IBD
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Questions topics:
› Current challenges in IBD clinical trials
› Adaptive Phase II/III trial designs
› Guselkumab’s Phase II/III trial in Crohn’s disease
› Novel clinical trials in IBD
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during July 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Most KOLs highlighted that recruitment is the greatest challenge in IBD clinical trials, both across Crohn’s disease & UC
Most KOLs flagged Phase II/III trials could accelerate development, but may limit ability to analyze data & adapt trial design
Most KOLs cited 8-12 weeks as being the minimum duration of a Phase II trial in IBD, with open-label extensions favored by all KOLs
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on Adaptive trial designs in IBD
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
AbbVie
Gilead
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.